CAMBRIDGE, Mass., Aug. 27, 2026, 3:16 p.m. EDT — Shares of Sarepta Therapeutics (NASDAQ: SRPT) rose 12.9% to $21.98 on Thursday, trading near the session high of $22.57. About 5.94 million shares had changed hands, versus a recent daily average of roughly 3.2 million.
The move added approximately $265 million to Sarepta’s equity value, lifting its market capitalization to about $2.32 billion. The price action is substantial; the fresh fundamental catalyst is much narrower.
A version update posted Thursday to ClinicalTrials.gov record NCT07542314 added Baylor College of Medicine as a site for ENHANCE, Sarepta’s 20-patient Phase 4 safety study of Elevidys with prophylactic sirolimus. The record still says “not yet recruiting.”
| ENHANCE field | Previous record | Aug. 26 update, posted Aug. 27 |
|---|---|---|
| Estimated enrollment | 20 participants | 20 participants |
| Study status | Not yet recruiting | Not yet recruiting |
| Estimated start | July 31, 2026 | Aug. 31, 2026 |
| Primary/final completion | March 31, 2027 | Aug. 31, 2027 |
| Locations | Original site set | Baylor College of Medicine added |
The added center modestly improves the trial’s operating footprint, but the dates moved in the opposite direction. The estimated start slipped by one month, while primary and final completion shifted five months later. Enrollment, endpoints and recruitment status did not improve.
That timetable matters because ENHANCE is designed to measure acute liver injury during the first 12 weeks after Elevidys treatment when sirolimus is added to the immunosuppressive regimen. In its latest Form 10-Q, Sarepta said any pathway to resume commercial dosing in non-ambulatory Duchenne patients depends on the FDA’s assessment of whether the sirolimus data improve Elevidys’ risk-benefit profile and on agreement over a label revision.
Thursday’s registry change is not a positive clinical readout, an FDA decision or the start of recruitment. Sarepta’s investor-relations release list showed no new company press release after Aug. 5 as of the market snapshot, and there was no disclosed acquisition agreement supporting takeover speculation.
Positioning can help explain why a procedural update coincided with an outsized move. The most recent published short-interest data showed about 27.05 million shares sold short, roughly 27% of the public float and 9.1 days of average trading volume, according to MarketBeat. A heavily shorted stock can rally quickly when momentum buyers arrive, but the same mechanics can accelerate a reversal.
The operating backdrop remains demanding. Second-quarter total revenue was $401.3 million, down 34% from a year earlier, while net product revenue fell 36% to $328.7 million. Elevidys revenue dropped 65% to $98.1 million; the older PMO portfolio was nearly flat at $230.6 million.
Sarepta reported $945.0 million of cash, investments and restricted cash against $847.6 million of carrying-value debt at June 30. Inventory totaled $1.13 billion, including a $11.6 million obsolescence write-down, and non-cancelable manufacturing commitments were $428.0 million. Those balances make demand recovery and label expansion financially important, not merely clinical milestones.
- Bull case: the Baylor addition helps ENHANCE activate, sirolimus data eventually support a broader Elevidys label, and high short interest extends the rally.
- Base case: investors treat the registry edit as procedural; SRPT consolidates while the market waits for recruitment and second-half DM1/FSHD data.
- Bear case: the five-month completion delay, boxed-warning risk and weak Elevidys sales outweigh the new site, causing the squeeze to fade.
The next verifiable signals are straightforward: a change from “not yet recruiting,” the first-patient milestone, any FDA update on the non-ambulatory pathway, and new company guidance on Elevidys demand. Until one appears, Thursday’s 13% gain says more about expectations and positioning than about new clinical evidence.
Related articles: Biotechnology
